ANTEOTECH LTD — AGM Information 2013

Oct 30, 2013

==> picture [290 x 147] intentionally omitted <==

Anteo Diagnostics (ASX:ADO)

Annual General Meeting 31[st] October 2013 Welcome

MEETING FORMAT

• Introductions

• Formal Resolutions

• CEO Report

• Other Business

• Meeting Close

==> picture [185 x 94] intentionally omitted <==

Introductions

Anteo Diagnostics Limited

 Mark Bouris– Non Executive Chairman

 Geoff Cumming – CEO

• Richard Martin – Executive Director

 Sandra Andersen – Non Executive Director  John Hurrell – Non Executive Director

Grant Thornton

• Matthew Bell – Partner

==> picture [185 x 94] intentionally omitted <==

Formal Resolutions

Resolution 1:

Adoption of Directors’ Remuneration Report

Resolution 2: Resolution 3: Resolution 4:

Election of Director (Mr John Hurrell)

Re - Election of Director (Mr Mark Bouris) Issue of 3,000,000 Options (Mr John Hurrell)

Issue of 6,000,000 Options (Dr Geoff Cumming)

Resolution 5: Resolution 6: Approval of 10% placement facility

==> picture [185 x 94] intentionally omitted <==

RESOLUTIONS – PROXY COUNT

	Description	For	Against	Open	Abstain	Totals
Resolution 1	Adoption of Directors’ Remuneration Report	213,920,864	13,576,457	19,868,474	1,514,450	247,365,795
Resolution 2	Election of Director( Mr John Hurrell)	209,578,975	4,000,063	34,512,706	788,501	248,091,744
Resolution 3	Re- Election of Director (Mr Mark Bouris)	209,419,275	4,162,263	34,510,206	788,501	248,091,744
Resolution 4	Issue of 3,000,000 Options (Mr John Hurrell)	207,688,892	5,804,605	34,302,176	1,084,572	247,795,673
Resolution 5	Issue of 6,000,000 Options (Dr Geoff Cumming)	208,456,592	5,036,905	34,302,176	1,084,572	247,795,673
Resolution 6	Approval of 10% placement facility	160,764,061	52,983,253	34,512,706	620,225	248,260,020

CEO UPDATE

==> picture [185 x 94] intentionally omitted <==

Mix&Go[TM] – A Universal “Glue” For Clinical Diagnostics, Life Sciences and Beyond

Investor Presentation October 2013 Dr. Geoff Cumming, CEO Anteo Diagnostics Ltd (ASX:ADO)

==> picture [309 x 151] intentionally omitted <==

Anteo Diagnostics Overview

==> picture [107 x 58] intentionally omitted <==

A Biotech company with highly experienced Board and Management team

D evelops, manufactures and commercialises proprietary surface coatings for healthcare industry O ur Mix&Go[TM] is a novel “glue” with a ubiquitous array of applications

Diagnostics (IVD) and Life Sciences (LS) – here and now

• Launch of commercial Mix&Go products in 2010

• Enables strong yet flexible binding of biomolecules to a broad variety of synthetic surfaces without causing damage to their structure or activity

• Improves the outcome of pathology tests, such as blood tests

• Commercial agreements with several companies: Bangs, Merck, Affymetrix, One World Lab, Gennova etc.

• Extensive patents protect technology and applications

• Cash flow positive through 2014

– Bioseparations the next opportunity

• Unique market opportunity to provide cost-effective solution

• Focus on rapidly growing therapeutics market

• Mix&Go makes it practical to replace current cumbersome methods with magnetic separation – a desirable but so far uneconomical solution

Anteo – Corporate Overview

==> picture [107 x 58] intentionally omitted <==

Business Model

Revenues from product sales Royalties from license agreements Paid R&D collaborations with IVD & LS companies

Proven Technology Platform

Proprietary technology licensed to major international healthcare companies with additional deals anticipated

Patented Technology

Significant and growing patent portfolio

Clear Development Path

Mix&Go development is progressing from diagnostics to next market sector: bioseparations Significant additional opportunities exist

Robust Deal Portfolio

Over 80 companies are actively assessing Mix&Go in-house or through collaborative work

Sound Commercialisation Strategy

Combination of licensing, collaborations and product sale provide diversified portfolio of revenue streams with clear path to profitability

Recent Highlights

==> picture [107 x 58] intentionally omitted <==

Commercial agreements

• 02/13 Partnership agreement with U.S. based One World Lab 02/13 Commenced paid feasibility study with global leader in lateral flow POC test manufacture

• 05/13 Sales partnership agreement with Spanish based Gennova Scientific for Europe & Latin America

• 06/13 Feasibility agreement with major global healthcare company for development of a POC device

• 08/13 Commenced further paid studies with lateral flow POC company

Patents

06/13 Granted European patent

08/13 Filed 2 new patent applications

Government Grants

07/13 Received 2-year $1.7m grant from Commercialisation Australia

Mix&Go – A Game Changing Technology

==> picture [602 x 347] intentionally omitted <==

Mix&Go - A Game Changing Technology

==> picture [107 x 58] intentionally omitted <==

Surface coatings are crucial in many industries and serve many purposes, e.g.:

• Provide adhesive properties, i.e. act like a “glue”

• Confer optical properties

• Add magnetic or electrical properties

Mix&Go is a universal “glue” that is uniquely suited for applications in diagnostics and life sciences:

• Gentle “glue” that maintains the activity of fragile biomolecules

• Improves pathology tests  earlier disease detection

• Reduces cost of test development and manufacture

• Applicable to numerous large healthcare segments:

• Pathology/diagnostic tests

• Point-of-care diagnostics

• Bioseparation

• Drug discovery and development

• Well suited to “glue” in a variety of applications and industries outside of healthcare, e.g. Resources and Cleantech

==> picture [107 x 58] intentionally omitted <==

Current Focus: Diagnostics and Life Sciences

Laboratory Diagnostics

Point-of-care

Rapid Test Products

==> picture [158 x 124] intentionally omitted <==

==> picture [190 x 168] intentionally omitted <==

• Global IVD: $44B (2011)

• Immunoassays: $8.8B

• Drivers: aging population = more tests, higher Asian demand, technology innovations

• $8 B (2011)

• $38B (2017 forecast)

• Drivers: price pressure, lack of qualified staff , need for immediate information, decentralisation, bedside testing

• $3.7B in 2012

• Drivers: decentralised testing, broadening applications, direct to consumer marketing

Life Science R&D

==> picture [140 x 71] intentionally omitted <==

• Very large and diverse

• Drivers: price pressure, efficiency

Mix&Go – The Secret Sauce

==> picture [107 x 58] intentionally omitted <==

==> picture [438 x 207] intentionally omitted <==

----- Start of picture text -----

3D structure is Orientation is Undamaged,
damaged random oriented
----- End of picture text -----

==> picture [223 x 203] intentionally omitted <==

----- Start of picture text -----

Proprietary solution:
metal polymers
----- End of picture text -----

Without Mix&Go

With Mix&Go

Consequences

Vast majority of proteins are nonfunctional

Lower sensitivity, LOD, dynamic range

More protein needed

Characteristics

Undamaged, fully functional proteins on surface

Less protein and/or beads required

Easy and fast to use and manufacture

Improved reproducibility

Benefits

Increased performance Less non-specific binding Improved protein stability

Reduced cost Saves valuable, expensive proteins

Improves efficiency Simpler test procedures Manufacturing faster, easier, more scalable Improved accuracy with improved %CV

The Proof Is In The Data

==> picture [107 x 58] intentionally omitted <==

Sensitivity Sensitivity improvement 4 to 50-fold!

Cost

More than 8-fold reduction in cost of goods sold

	Mix&Go™	Mix&Go™	Traditional	Traditional	Improvement
IL4	0.05 pg/mL		0.2 pg/mL		4x
Troponin I	5 pg/mL		50 pg/mL		10x
TNF-α	5 pg/mL		> 250 pg/mL		50x
HBcAg	<10 pg/mL		150 pg/mL		15x
TSH	<0.001 uIU/mL		0.006 uIU/mL		6x
		Mix&Go™		Traditional
Capture antibody (CaB) concentration		0.125 mg/mL		1.0 mg/mL
cAb Cost per Plate*		$1.10		$8.80
Plate Cost*		$0.55		$4.92
Total Cost		$1.65		$13.72
* Cost in AUD$

Stability

Stability even at high temperatures - better shelf life

==> picture [471 x 137] intentionally omitted <==

----- Start of picture text -----

Freshly Coated ° °
14 Days @ 25 C 14 Days @ 37 C
20,000
15,000
10,000
5,000
0
200 μg/mL 50 μg/mL 10 μg/mL
200 μg/mL 50 μg/mL 10 μg/mL 200 μg/mL 50 μg/mL 10 μg/mL
----- End of picture text -----

Mix&Go – Better Tests Faster!

==> picture [107 x 58] intentionally omitted <==

Mix&Go can improve all aspects of test development and manufacture so better tests can be developed faster

Performance Is Key, e.g. sensitivity, limit of detection

Fast Development Increases speed to market

Less Raw Materials Improved margins

==> picture [132 x 132] intentionally omitted <==

==> picture [132 x 132] intentionally omitted <==

==> picture [132 x 132] intentionally omitted <==

==> picture [131 x 132] intentionally omitted <==

==> picture [132 x 132] intentionally omitted <==

==> picture [132 x 132] intentionally omitted <==

New Test Possible for fragile proteins

Ease of Manufacture User-friendly, stable, robust

Scalable

From R&D to manufacturing without changes in procedure

– Bioseparations A Significant Market Opportunity

==> picture [579 x 359] intentionally omitted <==

Bioseparation or How to Get a Pure Protein

==> picture [107 x 58] intentionally omitted <==

Bioseparation : isolating rare proteins or cells from a complex mixture without contamination, e.g. the purification of

• Therapeutic antibodies/biologic drugs

• Vaccines for human and veterinary use

• Rare cells, e.g. stem cells or circulating tumor cells

• Proteins for R&D purposes

Anteo’s Solution: Mix&Go

• Enables preferred magnetic isolation approach which currently is too expensive

• Easy scale-up from R&D batches to large scale manufacturing batches

• Easy to automate, a critical aspect in large scale manufacturing

Mix&Go can change the way proteins are purified, positively impacting large industries from biological drug and vaccine manufacturing to stem cell research

Bioseparation – The Opportunity

Current Approach Chromatography:

• Time consuming

• Expensive

• Hard to automate

Paradigm Shift With Mix&Go magnetic separation can become reality

• technically superior solution

• economically advantageous

• Capacity constraints

Alternative

Magnetic separation:

• Technically superior

• • Currently unaffordable

Large Opportunity

• Protein and protein drug manufacturing: $3-5B

• Vaccine manufacturing: $620M in 2015

Leverage Mix&Go in bioseparations to create significant long-term revenue streams for Anteo

Bioseparations: Why Now?

==> picture [107 x 58] intentionally omitted <==

Internal Drivers

External Drivers

• Proof of concept - Mix&Go approaches show better performance than conventional methods

• Improvement - Mix&Go can generate novel, versatile approaches for bio-separation

• Patent Application Filed securing a strong IP position

• Increased importance Biologics/protein drugs play an ever more important role:7 out of the top 10 drugs sold in 2012 were biologics

• Market need - expressed desire by users to move to magnetic separation but unfavorable economics currently prevent that move

• Opportunity to move up value chain

• Global network and relationships developed through Mix&Go that will fast-track market penetration

• – an ever

• Changing needs increasing variety of biological molecules requiring new approaches

Additional Opportunities

==> picture [107 x 58] intentionally omitted <==

==> picture [68 x 199] intentionally omitted <==

Capitalise on Diagnostics/POC

==> picture [66 x 134] intentionally omitted <==

Expand on Diagnostics/POC Life Science Research

Capitalise on Bioseparations

Expand on Drug screening

Develop Bioseparations

==> picture [131 x 51] intentionally omitted <==

==> picture [131 x 50] intentionally omitted <==

==> picture [154 x 63] intentionally omitted <==

==> picture [154 x 76] intentionally omitted <==

==> picture [67 x 200] intentionally omitted <==

Capitalise on Diagnostics/POC Life Science Research

==> picture [66 x 131] intentionally omitted <==

Expand on Bioseparations

Initiate Bioseparations

Explore Cleantech,Resources Drug screening

Diagnostics/POC Life Science Research

Targets and Timeline

• Agreement with top-tier POC company

• 2-3 agreements with LS companies

• Agreement with top-tier POC company

• Agreement with midsize IVD

==> picture [199 x 76] intentionally omitted <==

==> picture [107 x 58] intentionally omitted <==

• Agreement w/ top tier IVD

• Agreement(s) w/ mid-tier IVD

• Agreement(s) w/ POC company

• Deal(s) w/ LS companies

==> picture [159 x 140] intentionally omitted <==

==> picture [50 x 19] intentionally omitted <==

==> picture [67 x 26] intentionally omitted <==

• Additional deals in IVD, POC and LS

• Agreements in bioseparations, resources, cleantech, other

Keypoints

==> picture [107 x 58] intentionally omitted <==

• Mix&Go is a proprietary platform technology with broad applicability in diagnostics, life sciences, bioseparations and beyond

• Mix&Go is proven licensed and gaining significant traction in commercial markets

• Mix&Go success means Anteo is becoming cash flow positive

• Focus on diagnostics and life sciences with expansion into bioseparations provides Anteo significant revenue opportunities

• Strong leadership - Board and management team in place to drive growth

• Global team resources and network to capitalise on growth opportunity

Anteo’s Mix&Go is an enabling technology beneficial to many industries and applications. Mix&Go is quickly gaining traction in the diagnostic and life sciences industries and has significant mid-term potential in bioseparations and long term in a large number of applications in health care and other industries.

OTHER BUSINESS AND QUESTION TIME

==> picture [185 x 94] intentionally omitted <==